Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

The Atom and the Algorithm: Nuclear Energy and AI are Converging to Shape the Future Writers and futurists have long echoed Alvin and Heidi Toffler’s idea that “the future arrives too fast…and in the ...

Transformer Weekly: Preemption’s out the NDAA, OpenAI’s ‘code red,’ and Anthropic’s IPO prep ...

By David Swanson, World BEYOND War Ah, those were the days. The UN had been blocked by a worldwide popular movement from approving of a war on Iraq. British Prime Minister Tony Blair had dragged the ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

The company appears to be on track to develop a commercialized product through its drug discovery system.

By Sriparna Roy Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the ...

A new NURBS-based algorithm is revolutionizing gridshell design by enabling faster, smoother, and more flexible shape-finding ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Ricursive Intelligence, a frontier AI lab with the mission to transform semiconductor design, launched today and announced its $35 ...